GF
LRMR icon

Gabelli Funds’s Larimar Therapeutics LRMR Stock Holding History

Gabelli Funds’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-1,833
Closed -$17K – 1076
2020
Q1 		$17K Buy
+1,833
New +$24.1K ﹤0.01% 1064
2019
Q4 		– Sell
-1,833
Closed -$16K – 1122
2019
Q3 		$16K Hold
1,833
– – ﹤0.01% 1117
2019
Q2 		$26K Buy
+1,833
New +$48.8K ﹤0.01% 1145

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
CA
CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Gabelli Funds's LRMR Position: Q2 2020 in Review

Gabelli Funds sold out of Larimar Therapeutics (LRMR) in Q2 2020, closing a stake of 1,833 shares — an estimated $17K sold.

Gabelli Funds first reported a position in LRMR in Q2 2019 and held it in 3 quarters. The position peaked at $26K in Q2 2019. 37 funds tracked by Wall St. Rank hold LRMR as of Q2 2020.

  • Gabelli Funds reported no remaining Larimar Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Gabelli Funds sold 1,833 Larimar Therapeutics shares in Q2 2020, an estimated $17K.
  • Gabelli Funds first reported a position in Larimar Therapeutics in Q2 2019 and held it in 3 quarters.
  • Gabelli Funds's Larimar Therapeutics position peaked at $26K in Q2 2019.
  • 37 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2020.

Based on Gabelli Funds's 13F filing for Q2 2020, filed 13 Aug 2020.